• Palonosetron Hydrochloride: Advances in Chemotherapy Antieme

  2026-05-29

  Ruhlmann & Herrstedt’s systematic review highlights palonosetron hydrochloride’s distinct pharmacologic attributes among 5-HT3 receptor antagonists, particularly its efficacy in preventing both acute and delayed chemotherapy-induced nausea and vomiting (CINV). The study’s findings inform the optimization of antiemetic regimens in oncology, with implications for translational research on supportive care.

• Dasatinib (BMS-354825): Reliable Strategies for Kinase Resea

  2026-05-29

  This scenario-driven guide addresses experimental challenges in kinase-focused cancer research using Dasatinib (BMS-354825), SKU A3017. By integrating data-backed protocols and addressing real lab pain points, it demonstrates how this inhibitor enhances reproducibility, workflow confidence, and data interpretation for assays involving Src, Bcr-Abl, and related pathways.

• Triiodothyronine (T3): Precision Tool for Metabolic Assays

  2026-05-28

  Leverage Triiodothyronine (T3) to unlock the full potential of thyroid hormone signaling pathway studies and advanced metabolic regulation research. This guide delivers protocol enhancements, troubleshooting strategies, and cross-referenced insights to improve reproducibility and data quality in your experimental workflows.

• Dasatinib (BMS-354825): Optimizing Kinase Research Assays

  2026-05-28

  Dasatinib (BMS-354825) delivers unmatched selectivity for Src and Bcr-Abl kinases, empowering researchers to dissect complex signaling in cancer biology. This guide unlocks actionable protocols, troubleshooting insights, and advanced translational workflows, anchored in the latest SNAI1–PIK3R2/p-EphA2 EMT research.

• Bile Acid Metabolism Subtypes Reveal Prognostic Markers in C

  2026-05-27

  Feng et al. identify new colorectal cancer (CRC) subtypes based on bile acid metabolism, linking CLCA1, UGT2A3, and ZG16 to immune dysfunction and clinical outcome. Their integrative approach highlights molecular markers that could refine prognosis and treatment responses in CRC.

• Apoptotic Extracellular Vesicles Promote LUAD Metastasis and

  2026-05-27

  The referenced study uncovers a mechanism by which tumor-derived apoptotic extracellular vesicles (apoEVs) drive metastasis and stemness in lung adenocarcinoma (LUAD). Through in vivo and in vitro approaches, the authors show that apoEVs enhance metastatic potential and self-renewal via SOX2 upregulation and ALDH1A1-mediated NF-κB signaling, highlighting the therapeutic potential of targeting apoEVs-ALDH1A1 interactions.

• Eltanexor (KPT-8602): Transforming XPO1 Inhibition for Cance

  2026-05-26

  Eltanexor (KPT-8602) redefines the landscape of cancer therapeutics targeting nuclear export, offering translational researchers an advanced, mechanistically validated tool. This article bridges mechanistic insight, experimental workflows, and strategic guidance to elevate translational research in leukemia, lymphoma, and colorectal cancer. Drawing on recent discoveries in Wnt/β-catenin pathway modulation and superior tolerability in vivo, we discuss how Eltanexor positions APExBIO at the forefront of next-generation cancer research tools.

• CD28-ARS2-PKM Axis Drives CD8+ T Cell Metabolic Flexibility

  2026-05-26

  Holling et al. reveal that CD28-mediated upregulation of ARS2 in CD8+ T cells orchestrates alternative splicing of the PKM gene, favoring PKM2 and facilitating metabolic flexibility crucial for antitumor immunity. This axis operates independently of canonical PI3K signaling, uncovering a distinct layer of immune metabolic regulation with translational implications for immunotherapy and metabolic assays.

• Semi-automated Discovery of Fast-Dissociating Anti-V5 Antibo

  2026-05-25

  Miyoshi et al. introduce a semi-automated, single-molecule microscopy approach for rapidly screening fast-dissociating, specific monoclonal antibodies directly from hybridoma cultures, including those targeting the V5 epitope tag. This innovation enables real-time, multiplex imaging and dynamic protein studies, improving the versatility of epitope tag-based workflows.

• 10058-F4 C-Myc-Max Inhibitor: Beyond Oncology to Stem Cell C

  2026-05-25

  Explore how 10058-F4, a potent c-Myc-Max dimerization inhibitor, enables precision targeting of transcription factor pathways in cancer and stem cell research. This article delivers advanced assay guidance and unique insights linking telomerase regulation with c-Myc inhibition.

• ELP-Mediated p21 Peptide Delivery Suppresses Glioblastoma Gr

  2026-05-24

  This study demonstrates that elastin-like polypeptide (ELP)-mediated delivery of a p21-derived peptide effectively suppresses proliferation in diverse glioblastoma cell lines through cytostatic, rather than apoptotic, mechanisms. The findings highlight the potential of ELP-based carriers to overcome delivery barriers for peptide therapeutics in aggressive brain tumors, offering a foundation for future translational research.

• Tariquidar (XR9576): Precision Inhibition in Complex Tumor M

  2026-05-23

  This thought-leadership article explores the mechanistic rationale and translational impact of using Tariquidar (XR9576) for advanced drug resistance research. Building on breakthrough findings that link tumor microenvironment viscosity to chemoresistance via P-glycoprotein upregulation, the article integrates state-of-the-art mechanobiology with strategic workflow guidance. Readers will find actionable protocol parameters, competitive analysis, and a forward-looking perspective on overcoming transporter-mediated challenges in cancer models, with direct attribution to APExBIO’s Tariquidar for research excellence.

• Vincristine Sulfate: Workflow Optimization in Cancer Researc

  2026-05-22

  Vincristine sulfate is a gold-standard microtubule disrupter essential for precision-driven cancer research, offering validated efficacy from cell models to xenografts. This article delivers advanced protocol guidance, troubleshooting strategies, and direct links to translational advantages, empowering researchers to maximize reproducibility and antitumor insights.

• Dasatinib Monohydrate in Complex Tumor Microenvironment Mode

  2026-05-22

  Explore how Dasatinib Monohydrate advances kinase inhibition research in physiologically relevant tumor microenvironment models. This article highlights critical assay design insights and practical guidance for translational oncology.

• Radicicol: Hsp90 Inhibitor Workflows for Apoptosis & Inflamm

  2026-05-21

  Radicicol stands out as a multi-target Hsp90 inhibitor, streamlining apoptosis, inflammation, and adipogenesis research with unmatched specificity and workflow flexibility. This guide delivers actionable protocol enhancements, troubleshooting insights, and fresh context from leading bench studies—optimizing the impact of APExBIO’s Radicicol solution across diverse experimental models.

16190 records 1/1080 page Next 12345 下5页 Last page